GLP-1 receptor agonists have become one of the most talked-about developments in weight management. Originally developed for type 2 diabetes, these injectable medications have shown remarkable effectiveness for weight loss when used under specialist supervision. This article covers how they work, who may benefit, what results to expect, and important safety considerations.
What are GLP-1 medications?
GLP-1 (glucagon-like peptide-1) receptor agonists are medications that mimic natural gut hormones involved in appetite regulation and blood sugar control. They reduce hunger, slow stomach emptying, and improve insulin sensitivity — leading to meaningful weight loss in people who meet the clinical criteria.
Two medications are currently at the forefront of medical weight loss:
Semaglutide (brand names: Ozempic for diabetes, Wegovy for weight loss) targets the GLP-1 receptor. It has been available longer and has an extensive body of clinical evidence supporting its use.
Tirzepatide (brand name: Mounjaro) targets both the GLP-1 and GIP receptors — a dual mechanism. It is newer to the market but has shown strong results in clinical trials.
How they compare
| Semaglutide (Ozempic / Wegovy) | Tirzepatide (Mounjaro) | |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | GLP-1 + GIP dual agonist |
| Average weight loss (trials) | 15–17% of body weight | 20–22% of body weight |
| Injection frequency | Once weekly | Once weekly |
| Available in India | Yes (Ozempic widely available; Wegovy limited) | Yes (recently launched) |
| Approximate monthly cost (India) | ₹8,000–15,000 | ₹12,000–20,000 |
| Common side effects | Nausea, vomiting (usually first 2-4 weeks) | Nausea, diarrhoea (usually first 2-4 weeks) |
| Safety track record | Longer (7+ years of data) | Newer (strong trial data, shorter real-world history) |
| Typical treatment duration | 12–18 months | 12–18 months |
Both medications are effective. Each has different characteristics, and the right choice depends on the individual patient's medical profile, existing conditions, and how their body responds. This is a decision that should be made with a specialist after proper evaluation — not based on a comparison chart alone.
Who qualifies for GLP-1 therapy?
GLP-1 medications are not intended for cosmetic weight loss. Medical guidelines establish clear criteria for who is likely to benefit:
Generally appropriate for: individuals with a BMI above 30, or a BMI above 27 with a weight-related condition such as type 2 diabetes, hypertension, sleep apnoea, or PCOS. For South Asian populations, lower BMI thresholds (25+) with metabolic risk factors may be clinically appropriate, given the higher susceptibility to insulin resistance in this population.
Not appropriate for: individuals with a personal or family history of medullary thyroid cancer, MEN2 syndrome, or pancreatitis. These medications are also not recommended during pregnancy or for those planning pregnancy.
GLP-1 medications are hormonal drugs that affect the pancreas, gut, thyroid axis, and metabolic rate. Starting without baseline blood work — thyroid function, kidney function, insulin levels, lipid panel — risks missing underlying conditions that need treatment first. The dose must also be titrated slowly over weeks; starting too high causes severe nausea and dehydration. Self-prescribing or obtaining these medications without medical oversight carries real risks.
What a proper evaluation looks like
Before starting GLP-1 therapy, a thorough metabolic assessment should be performed. This typically includes:
Metabolic panel: Fasting glucose, HbA1c, fasting insulin levels, lipid panel, thyroid function (TSH, free T4), liver function, kidney function, and vitamin D. This helps determine whether weight gain is driven by hormonal factors (thyroid dysfunction, PCOS, cortisol excess) or primarily lifestyle-related — which significantly changes the treatment approach.
Body composition: Weight alone does not tell the full story. Fat percentage, visceral fat, muscle mass, and metabolic age provide a more complete picture. Two individuals at the same weight can have very different metabolic profiles.
Personalised treatment plan: If GLP-1 therapy is appropriate, treatment typically starts at the lowest dose and titrates upward every 4 weeks. It is most effective when combined with structured dietary modification, activity guidance, and in some cases, CGM (continuous glucose monitoring) to track metabolic responses in real time.
Expected results
Setting realistic expectations is important. Based on clinical evidence and real-world outcomes:
Month 1: Typically 2–4 kg of weight loss. Appetite reduction is the primary mechanism at this stage. Mild nausea is common but usually subsides.
Months 2–4: Weight loss often accelerates to 1–2 kg per week as the dose reaches therapeutic levels. Appetite is significantly reduced, cravings decrease, and portions naturally get smaller.
Months 6–12: Cumulative loss of 12–20% of starting body weight is typical. A person starting at 100 kg may reach 80–88 kg. Blood sugar, blood pressure, and cholesterol levels often improve along the way — sometimes enough to reduce other medications.
After stopping treatment: Some weight regain is common — studies indicate 30–50% of lost weight may return if the medication is discontinued without established lifestyle changes. This is why building sustainable eating and exercise habits during the treatment window is a critical part of the programme.
GLP-1 therapy is currently the most effective non-surgical approach to weight loss available. It works best as part of a comprehensive plan that includes metabolic evaluation, specialist monitoring, and structured lifestyle modification — not as a standalone treatment.
Frequently asked questions
"Will I regain weight after stopping?" — Some regain is common, which is why lifestyle habit formation during treatment is essential. The goal is to use the appetite-reduction window to build eating patterns that are sustainable long-term.
"Are they safe long-term?" — Semaglutide has safety data spanning over 7 years. Tirzepatide is newer but supported by strong clinical trial evidence. Both are approved by the FDA and DCGI. The most common side effects (nausea, constipation) are generally manageable and tend to be temporary.
"Can these be taken alongside diabetes medication?" — Yes, but doses of existing medications may need adjustment. Combining GLP-1 therapy with certain diabetes drugs can increase the risk of hypoglycaemia if not properly managed — which is why specialist oversight is important.
"Is diet still necessary while on the medication?" — Yes. The medication reduces appetite, but what is eaten still matters for overall health, nutrition, and long-term results. A structured eating plan — focused on sustainability rather than restriction — is an important part of the treatment.